EGFR and non-small cell lung carcinoma: Approximately 20% of individuals diagnosed with non-small cell lung cancer (NSCLC) harbor a distinct genetic mutation in the epidermal growth factor receptor (EGFR) gene, referred to as an activating somatic mutation [1].